2025/03/01 by William E. Rosenfeld · 1 voice
Medicine · Neuroscience · #Epilepsy research and treatment #Pharmacological Effects and Toxicity Studies #Neuroscience and Neuropharmacology Research
paper · pdf · doi:10.1111/epi.18305
openalex publication_date 2025/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/16
Seizure freedom is an important therapeutic goal for people with epilepsy and is associated with improved quality of life and reduced morbidity and mortality. Yet despite the use of multiple antiseizure medications (ASMs; either as monotherapy or in combination), seizures persist in approximately one third of patients. Third-generation ASMs, such as lacosamide, eslicarbazepine, perampanel, and brivaracetam, have demonstrated good efficacy in terms of reductions in the frequency of focal seizures. The newest ASM, cenobamate, which is indicated for the treatment of focal seizures in adults, has demonstrated notable rates of seizure freedom for some patients with drug-resistant epilepsy. In long-term, open-label clinical studies of adjunctive cenobamate, between 18.4% and 36.3% of patients achieved seizure freedom for a consecutive ≥12-month duration, and 1-year retention rates ranged from 73% to 83%. This article reviews some of the potential treatment barriers encountered during the medication management of patients with epilepsy that may impede the use and optimization of newer ASMs like cenobamate. These include treatment complacency, inadequate trial of new adjunctive therapies ("last in, first out"), pitfalls of rational polytherapy, and restricting the use of newer drugs. Although treatment must always be tailored to the specific patient, clinicians should consider the potential benefits of newer therapies and continue to reassess and optimize ASM treatment to achieve the best outcomes for their patients.